{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:45:41Z","timestamp":1769820341044,"version":"3.49.0"},"reference-count":55,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Intramural\/Extramural research program of the NCATS, NIH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The hippo signaling pathway is a central tumor suppressor cascade frequently inactivated in selected human cancers, leading to the aberrant activation of TEAD transcription factors. Whereas several TEAD auto-palmitoylation inhibitors are currently in development, a comprehensive assessment of this novel drug-modality is missing. Here, we report a comparative analysis among six TEADi(s) using cell-based and biochemical assays in Hippo pathway deficient mesothelioma. Our analysis revealed varying potency and selectivity across TEADi, also highlighting their limited efficacy. To overcome this limitation, we performed an unbiased, quantitative high-throughput drug screening by combining the TEADi VT-103 with a library of approximately 3000 oncology-focused drugs. By exploiting this library\u2019s mechanistic redundancy, we identified several drug-classes robustly synergized with TEADi. These included glucocorticoid-receptor (GR) agonists, Mek1\/2 inhibitors, mTOR inhibitors, and PI3K inhibitors, among others. Altogether, we report a coherent single-agent dataset informing on potency and selectivity of TEAD-palmitoylation inhibitors as single-agents. We also describe a rational pipeline enabling the systematic identification of TEAD druggable co-dependencies. This data should support the pre-clinical development of drug combination strategies for the treatment of Hippo-deficient mesothelioma, and more broadly, for other cancers dependent on the oncogenic activity of YAP\/TEAD.<\/jats:p>","DOI":"10.3390\/ph16121635","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:24:13Z","timestamp":1700562253000},"page":"1635","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma"],"prefix":"10.3390","volume":"16","author":[{"given":"Lale","family":"Evsen","sequence":"first","affiliation":[{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":false,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer","volume":"163","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","article-title":"Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1101\/gad.173435.111","article-title":"Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis","volume":"26","author":"Zhao","year":"2012","journal-title":"Genes Dev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1101\/gad.1602907","article-title":"Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control","volume":"21","author":"Zhao","year":"2007","journal-title":"Genes Dev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.1843810","article-title":"A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)","volume":"24","author":"Zhao","year":"2010","journal-title":"Genes Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.trecan.2020.04.004","article-title":"The Hippo Pathway as a Driver of Select Human Cancers","volume":"6","author":"Kulkarni","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/cells11081370","article-title":"Genomic Hippo Pathway Alterations and Persistent YAP\/TAZ Activation: New Hallmarks in Head and Neck Cancer","volume":"11","author":"Faraji","year":"2022","journal-title":"Cells"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2013.08.025","article-title":"Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin\/NF2","volume":"154","author":"Yin","year":"2013","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1161995","DOI":"10.3389\/ftox.2023.1161995","article-title":"NF2 alteration in mesothelioma","volume":"5","author":"Sekido","year":"2023","journal-title":"Front. Toxicol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","article-title":"Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy","volume":"23","author":"Pobbati","year":"2015","journal-title":"Structure"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nchembio.2036","article-title":"Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway","volume":"12","author":"Chan","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.str.2015.11.005","article-title":"Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling","volume":"24","author":"Noland","year":"2016","journal-title":"Structure"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1073\/pnas.1819400116","article-title":"Cell contact and Nf2\/Merlin-dependent regulation of TEAD palmitoylation and activity","volume":"116","author":"Kim","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1038\/s41598-022-09127-7","article-title":"The role of lysine palmitoylation\/myristoylation in the function of the TEAD transcription factors","volume":"12","author":"Mesrouze","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112388","DOI":"10.1016\/j.celrep.2023.112388","article-title":"Lysine long-chain fatty acylation regulates the TEAD transcription factor","volume":"42","author":"Noritsugu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107809","DOI":"10.1016\/j.celrep.2020.107809","article-title":"Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling","volume":"31","author":"Holden","year":"2020","journal-title":"Cell Rep."},{"key":"ref_18","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.stem.2020.03.002","article-title":"Lats1\/2 Sustain Intestinal Stem Cells and Wnt Activation through TEAD-Dependent and Independent Transcription","volume":"26","author":"Li","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.apsb.2021.04.015","article-title":"Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3","volume":"11","author":"Lu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e78810","DOI":"10.7554\/eLife.78810","article-title":"Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling","volume":"11","author":"Fan","year":"2022","journal-title":"Elife"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1021823","DOI":"10.3389\/fonc.2022.1021823","article-title":"Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity","volume":"12","author":"Gridnev","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e78810","DOI":"10.7554\/eLife.80210","article-title":"Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode","volume":"11","author":"Hu","year":"2022","journal-title":"Elife"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, Y., Ning, C., Yue, J., Zhang, C., He, X., Wang, Y., and Liu, Z. (2022). Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation. Comput. Biol. Chem., 98.","DOI":"10.1016\/j.compbiolchem.2022.107648"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/s41467-022-34559-0","article-title":"Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells","volume":"13","author":"Sun","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1021\/acs.jmedchem.2c01548","article-title":"Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors","volume":"66","author":"Lu","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","article-title":"Therapeutic targeting of TEAD transcription factors in cancer","volume":"48","author":"Pobbati","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1038\/s41467-023-39527-w","article-title":"Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens","volume":"14","author":"Barbosa","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9206","DOI":"10.1021\/acs.jmedchem.2c00403","article-title":"Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106","volume":"65","author":"Heinrich","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molcel.2015.09.001","article-title":"YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers","volume":"60","author":"Galli","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41556-020-0485-0","article-title":"Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression","volume":"22","author":"Lu","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","article-title":"Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4","volume":"24","author":"Zanconato","year":"2018","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.celrep.2015.09.014","article-title":"Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins","volume":"13","author":"Wang","year":"2015","journal-title":"Cell Rep."},{"key":"ref_36","unstructured":"Ceribelli, D.D.M., Hoyt, S., Morris, P., Tosto, F.A., and Thomas, C.J. (2023). LATS Inhibitors and Uses. (No. PCT\/US23\/24589), Thereof. Patent."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1038\/srep13891","article-title":"High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations","volume":"5","author":"Mott","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: Current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: Oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules","volume":"20","author":"Henley","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/13543776.2022.2096436","article-title":"Progress with YAP\/TAZ-TEAD inhibitors: A patent review (2018-present)","volume":"32","author":"Zagiel","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/13543776.2018.1549226","article-title":"Hippo pathway inhibition by blocking the YAP\/TAZ-TEAD interface: A patent review","volume":"28","author":"Crawford","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/acschembio.9b00786","article-title":"Identification of Quinolinols as Activators of TEAD-Dependent Transcription","volume":"14","author":"Pobbati","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-20-0706","article-title":"Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways","volume":"11","author":"Pham","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e1021441","DOI":"10.1080\/23723556.2015.1021441","article-title":"The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors","volume":"3","author":"Lin","year":"2016","journal-title":"Mol. Cell Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e202200303","DOI":"10.1002\/cmdc.202200303","article-title":"The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition","volume":"17","author":"Furet","year":"2022","journal-title":"ChemMedChem"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"LB319","DOI":"10.1158\/1538-7445.AM2023-LB319","article-title":"IAG933, a selective and orally efficacious YAP1\/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations","volume":"83","author":"Schmelzle","year":"2023","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ncb3581","article-title":"Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation","volume":"19","author":"Lin","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tibs.2017.09.003","article-title":"Regulation of the Hippo Pathway Transcription Factor TEAD","volume":"42","author":"Lin","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/12\/1635\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:59Z","timestamp":1760131559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/12\/1635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ph16121635"],"URL":"https:\/\/doi.org\/10.3390\/ph16121635","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}